Penumbra (NYSE:PEN) announced additional results from its STORM-PE trial of computer-assisted vacuum thrombectomy (CAVT).
Global and Indian data paint a complex picture, where men often underuse health services, delay care and score lower on some health-literacy measures.
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
Penumbra reported positive data for a trial of its treatment for pulmonary embolism. The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, ...
Privacy advocates urge the FTC to block Meta’s plan to use chatbot conversations for "tailoring" content and ads served ...
It would appear rest is still being downplayed and undervalued in workplaces. Is it time to enforce lunch breaks?
Straight Arrow News on MSNOpinion
Normalizing Nazis: How extremism moved from fringe to mainstream
Nazi imagery and symbolism are increasingly moving from the darkest corners of American society to its political mainstream, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback